20160793 - Barredo Julio
-
Investigator:
Julio Barredo
Email
Coordinator: Eva Pavicic
+1 (305) 2437846
IRB: 20160793
SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: Moffitt Cancer Center
Enrolling Sites:
JMH
SylvesterTitle: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"
ARST1431 - Barredo, Julio
-
Investigator:
Julio Barredo
Email
Coordinator: Nuria Garantiva
+1 (786) 2743477
IRB: 20170069
SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: COG
Enrolling Sites:
JMH
SylvesterTitle: ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Eligibility Criteria - NCT02567435 *This information has been extracted from " www.clinicaltrials.gov"
19487 - Barredo, Julio
-
Investigator:
Julio Barredo
Email
Coordinator: Eva Pavicic
+1 (305) 2437846
IRB: 20181082
SDG: Pediatric Cancer
Disease Site(s): Bones and Joints
Sponsor: Moffitt Cancer Center
Enrolling Sites:
JMH
SylvesterTitle: 19487: A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Eligibility Criteria - NCT03628209 *This information has been extracted from " www.clinicaltrials.gov"
TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple
Sponsor: ASCO
Enrolling Sites:
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20201132 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Mirna Gonzalez
+1 (305) 2432441
IRB: 20201132
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: Tracon
Enrolling Sites:
Sylvester
Title: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Eligibility Criteria - NCT04480502 *This information has been extracted from " www.clinicaltrials.gov"
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH EAY131)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
VYR-VSV2-101 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20170023
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Lung,Melanoma, skin,Kaposis sarcoma
Sponsor: VYRIAD
Enrolling Sites:
Sylvester
Title: Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNß-NIS), in Patients with Refractory Solid Tumors
Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"
20190762 - Penedo Frank
-
Investigator:
Frank Penedo
Email
Coordinator:
IRB: 20190762
SDG: Population Sciences
Disease Site(s): Lip, Oral Cavity and Pharynx,Esophagus,Breast,Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Other Male Genital,Bladder,Kidney,Other Urinary,Thyroid,Other Endocrine System,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Larynx,Lung,Other Respiratory and Intrathoracic Organs,Bones and Joints,Soft Tissue,Melanoma, skin,Kaposis sarcoma
Sponsor: SCCC
Enrolling Sites:
Sylvester
Title: Development of an eHealth-based Cognitive Behavioral Stress and Self-Management Intervention to Reduce Symptom Burden in HIV+ Gay and Bisexual MSM Treated for Non-Metastatic Cancer
Eligibility Criteria - NCT04544917 *This information has been extracted from " www.clinicaltrials.gov"
AMC- 096 - Ramos, Juan Carlos
-
Investigator:
Juan Carlos Ramos
Email
Coordinator: Sarah Lam
+1 (305) 2438143
IRB: 20180804
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Kaposis sarcoma
Sponsor: AMC
Enrolling Sites:
Sylvester
Title: AMC-096: A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Eligibility Criteria - NCT02799485 *This information has been extracted from " www.clinicaltrials.gov"
AMC 098 - Ramos, Juan Carlos
-
Investigator:
Juan Carlos Ramos
Email
Coordinator: Sarah Lam
+1 (305) 2438143
IRB: 20180856
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Kaposis sarcoma
Sponsor: AMC
Enrolling Sites:
Sylvester
Title: AMC-098:A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Eligibility Criteria - NCT03077451 *This information has been extracted from " www.clinicaltrials.gov"
Anlotinib AL3818-US-004A - Trent, Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator: Mirna Gonzalez
+1 (305) 2432441
IRB: 20170072
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: ADVENCHEN LABORATORIES
Enrolling Sites:
Sylvester
Title: AL3818-US-004A: Phase III Study of AL3818 (Anlotinib) HydrochlorideMonotherapy in Subjects with Metastatic or AdvancedAlveolar Soft Part Sarcoma, Leiomyosarcoma and SynovialSarcoma
Eligibility Criteria - NCT03016819 *This information has been extracted from " www.clinicaltrials.gov"